Clinical management of infections caused by multidrug-resistant Enterobacteriaceae

Therapeutic Advances in Infectious Disease

Volumn 1, Issue 2, 2013, Pages 49-69

  Delgado Valverde, Mercedes ^a   Sojo Dorado, Jesus ^a   Pascual, Alvaro ^a   Rodriguez Bano, Jesus ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84993782410     PISSN: 20499361     EISSN: 2049937X     Source Type: Journal    
DOI: 10.1177/2049936113476284     Document Type: Review

References (175)

1. Aggen J. Armstrong E. Goldblum A. Dozzo P. Linsell M. Gliedt M. et al (2010) Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother. 54: 4636–4642.
2. Albur M. Noel A. Bowker K. MacGowan A. (2012) Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae. Antimicrob Agents Chemother. 56: 3441–3443.
3. Ambler R. (1980) The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci. 289: 321–331.
4. Anderson K. Lonsway D. Rasheed J. Biddle J. Jensen B. McDougal L. et al (2007) Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol. 45: 2723–2725.
5. Balakrishnan I. Awad-El-Kariem F. Aali A. Kumari P. Mulla R. Tan B. et al (2011) Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and / or derepressed AmpC beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 66: 2628–2631.
6. Barnaud G. Benzerara Y. Gravisse J. Raskine L. Sanson-Le Pors M. Labia R. et al (2004) Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate. Antimicrob Agents Chemother. 48: 1040–1042.
7. Bassetti M. Righi E. Fasce R. Molinari M. Rosso R. Di Biagio A. et al (2007) Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit. J Antimicrob Chemother. 60: 433–435.
8. Baudry P. Nichol K. de Corby M. Mataseje L. Mulvey M. Hoban D. et al (2008) Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units. Antimicrob Agents Chemother. 52: 1846–1849.
9. Bin C. Hui W. Renyuan Z. Yongzhong N. Xiuli X. Yingchun X. et al (2006) Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis. 56: 351–357.
10. Boehr D. Daigle D. Wright G. (2004) Domain–domain interactions in the aminoglycoside antibiotic resistance enzyme AAC(6')-APH(2''). Biochemistry. 43: 9846–9855.
11. Bulik C. Nicolau D. (2010) In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumonia. Antimicrob Agents Chemother. 54: 4112–4115.
12. Bulik C. Nicolau D. (2011) Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumonia. Antimicrob Agents Chemother. 55: 3002–3004.
13. Bush K. (2012) Improving known classes of antibiotics: an optimistic approach for the future. Curr Opin Pharmacol. 12: 527–534.
14. Bush K. Jacoby G. (2010) Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 54: 969–976.
15. Bush K. Jacoby G. Medeiros A. (1995) A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 39: 1211–1233.
16. Canton R. Akova M. Carmeli Y. Giske C. Glupczynski Y. Gniadkowski M. et al (2012) Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect. 18: 413–431.
17. Canton R. Coque T. (2006) The CTX-M beta-lactamase pandemic. Curr Opin Microbiol. 9: 466–475.
18. Carmeli Y. (2008) Strategies for managing today's infections. Clin Microbiol Infect. 14(Suppl. 3): 22–31.
19. Carrer A. Poirel L. Yilmaz M. Akan O. Feriha C. Cuzon G. et al (2010) Spread of OXA-48-encoding plasmid in Turkey and beyond. Antimicrob Agents Chemother. 54: 1369–1373.
20. Castanheira M. Sader H. Farrell D. Mendes R. Jones R. (2012) Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more beta-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. Antimicrob Agents Chemother. 56: 4779–4785.
21. Cheong, H., Ko, K., Kang, C., Chung, D., Peck, K. and Song, J. (2012) Clinical significance of infections caused by plasmid-mediated AmpC beta-lactamases and extended-spectrum beta-lactamase-producing Escherichia coli. Infection 12 September (Epub ahead of print). DOI 10.1007/s15010–012–0341-7.
22. Chitnis A. Caruthers P. Rao A. Lamb J. Lurvey R. Beau de Rochars V. et al (2012) Outbreak of carbapenem-resistant enterobacteriaceae at a long-term acute care hospital: sustained reductions in transmission through active surveillance and targeted interventions. Infect Control Hosp Epidemiol. 33: 984–992.
23. Cho S. Kang C. Chung D. Peck K. Song J. Jang J. (2012) Breakthrough bacteremia due to extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae during combination therapy with colistin and tigecycline. Antimicrob Agents Chemother. 56: 4994–4995. author reply 4996.
24. Choi S. Lee J. Park S. Choi S. Lee S. Jeong J. et al (2008) Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother. 52: 995–1000.
25. Chow J. Fine M. Shlaes D. Quinn J. Hooper D. Johnson M. et al (1991) Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 115: 585–590.
26. CLSI (2010) Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational supplement (June 2010 update). Wayne, PA: Clinical and Laboratory Standards Institute.
27. Collins V. Marchaim D. Pogue J. Moshos J. Bheemreddy S. Sunkara B. et al (2012) Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 56: 2173–2177.
28. Conejo M. Hernandez J. Pascual A. (2008) Effect of porin loss on the activity of tigecycline against Klebsiella pneumoniae producing extended-spectrum beta-lactamases or plasmid-mediated AmpC-type beta-lactamases. Diagn Microbiol Infect Dis. 61: 343–345.
29. Daikos G. Markogiannakis A. (2011) Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect. 17: 1135–1141.
30. Dalfino L. Puntillo F. Mosca A. Monno R. Spada M. Coppolecchia S. et al (2012) High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 54: 1720–1726.
31. Dandekar P. Maglio D. Sutherland C. Nightingale C. Nicolau D. (2003) Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy. 23: 988–991.
32. de Cueto M. López L. Hernández J. Morillo C. Pascual A. (2006) In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob Agents Chemother. 50: 368–370.
33. Ding H. Yang Y. Lu Q. Wang Y. Chen Y. Deng L. et al (2008) The prevalence of plasmid-mediated AmpC beta-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae from five children's hospitals in China. Eur J Clin Microbiol Infect Dis. 27: 915–921.
34. Doi Y. Arakawa Y. (2007) 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin Infect Dis. 45: 88–94.
35. Dubois V. Poirel L. Marie C. Arpin C. Nordmann P. Quentin C. (2002) Molecular characterization of a novel class 1 integron containing bla(GES-1) and a fused product of aac3-Ib/aac6'-Ib' gene cassettes in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 46: 638–645.
36. Elliott E. Brink A. van Greune J. Els Z. Woodford N. Turton J. et al (2006) In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase. Clin Infect Dis. 42: 95–98.
37. Endimiani A. Hujer K. Hujer A. Armstrong E. Choudhary Y. Aggen J. et al (2009) ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 53: 4504–4507.
38. Endimiani A. Hujer K. Hujer A. Pulse M. Weiss W. Bonomo R. (2011) Evaluation of ceftazidime and NXL 104 in two murine models of infection due to KPC-producing Klebsiella pneumonia. Antimicrob Agents Chemother. 55: 82–85.
39. Endimiani A. Luzzaro F. Perilli M. Lombardi G. Coli A. Tamborini A. et al (2004) Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis. 38: 243–251.
40. EUCAST (2012) Breakpoint tables for interpretation of MICs and zone diameters. Version 2.0. European Committee on Antimicrobial Susceptibility Testing. Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_2.0_120221.pdf (accessed 10 January 2012).
41. Falagas M. Karageorgopoulos D. Nordmann P. (2011) Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future Microbiol. 6: 653–666.
42. Falagas M. Kasiakou S. (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 40: 1333–1341.
43. Falagas M. Kastoris A. Kapaskelis A. Karageorgopoulos D. (2010 a) Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 10: 43–50.
44. Falagas M. Vouloumanou E. Togias A. Karadima M. Kapaskelis A. Rafailidis P. et al (2010 b) Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 65: 1862–1877.
45. Florescu D. Qiu F. McCartan M. Mindru C. Fey P. Kalil A. (2012) What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis. 54: 670–680.
46. Frei C. Wiederhold N. Burgess D. (2008) Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother. 61: 621–628.
47. Fritsche T. Castanheira M. Miller G. Jones R. Armstrong E. (2008) Detection of methyltransferases conferring high-level resistance to aminoglycosides in enterobacteriaceae from Europe, North America, and Latin America. Antimicrob Agents Chemother. 52: 1843–1845.
48. Galani I. Souli M. Daikos G. Chrysouli Z. Poulakou G. Psichogiou M. et al (2012) Activity of Plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J Chemother. 24: 191–194.
49. Galimand M. Courvalin P. Lambert T. (2003) Plasmid-mediated high-level resistance to aminoglycosides in Enterobacteriaceae due to 16S rRNA methylation. Antimicrob Agents Chemother. 47: 2565–2571.
50. Gasink L. Edelstein P. Lautenbach E. Synnestvedt M. Fishman N. (2009) Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol. 30: 1180–1185.
51. Glupczynski Y. Huang T. Bouchahrouf W. Rezende de Castro R. Bauraing C. Gerard M. et al (2012) Rapid emergence and spread of OXA-48-producing carbapenem-resistant Enterobacteriaceae isolates in Belgian hospitals. Int J Antimicrob Agents. 39: 168–172.
52. Goethaert K. van Looveren M. Lammens C. Jansens H. Baraniak A. Gniadkowski M. et al (2006) High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. Clin Microbiol Infect. 12: 56–62.
53. Han J. Kasahara K. Edelstein P. Bilker W. Lautenbach E. (2012) Risk factors for infection or colonization with CTX-M extended-spectrum-beta-lactamase-positive Escherichia coli. Antimicrob Agents Chemother. 56: 5575–5580.
54. Harris P. Ferguson J. (2012) Antibiotic therapy for inducible AmpC beta-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents. 40: 297–305.
55. Hawser S. Bouchillon S. Hoban D. Badal R. Hackel M. Lascols C. et al (2012) Low frequency of ertapenem-resistant intra-abdominal isolates of Escherichia coli from Latin America: susceptibility, ESBL-occurrence, and molecular characterisation (SMART 2008–2009). J Chemother. 24: 6–11.
56. Hirsch E. Ledesma K. Chang K. Schwartz M. Motyl M. Tam V. (2012) In vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 56: 3753–3757.
57. Hirsch E. Tam V. (2010) Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 65: 1119–1125.
58. Hoban D. Bouchillon S. Hawser S. Badal R. (2010) Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007. Diagn Microbiol Infect Dis. 66: 78–86.
59. Hoban D. Lascols C. Nicolle L. Badal R. Bouchillon S. Hackel M. et al (2012) Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009–2010. Diagn Microbiol Infect Dis. 74: 62–67.
60. Hooper D. (2000) Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis. 31(Suppl. 2): S24–S28.
61. Hope R. Warner M. Potz N. Fagan E. James D. Livermore D. (2006) Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England. J Antimicrob Chemother. 58: 1312–1314.
62. Houghton J. Green K. Chen W. Garneau-Tsodikova S. (2010) The future of aminoglycosides: the end or renaissance? Chembiochem. 11: 880–902.
63. Hsueh P. (2012) Study for Monitoring Antimicrobial Resistance Trends (SMART) in the Asia-Pacific region, 2002–2010. Int J Antimicrob Agents. 40(Suppl): S1–S3.
64. Hussein K. Sprecher H. Mashiach T. Oren I. Kassis I. Finkelstein R. (2009) Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol. 30: 666–671.
65. Jacoby G. (2005) Mechanisms of resistance to quinolones. Clin Infect Dis. 41(Suppl. 2): S120–S126.
66. Jacoby G. (2009) AmpC beta-lactamases. Clin Microbiol Rev. 22: 161–182.
67. Jones R. Kirby J. Rhomberg P. (2008) Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagn Microbiol Infect Dis. 61: 203–213.
68. Kang C. Kim S. Park W. Lee K. Kim H. Kim E. et al (2005) Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother. 49: 760–766.
69. Kang C. Pai H. Kim S. Kim H. Kim E. Oh M. et al (2004) Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase. J Antimicrob Chemother. 54: 1130–1133.
70. Kang C. Song J. Kim S. Chung D. Peck K. Thamlikitkul V. et al (2012) Risk factors and pathogenic significance of bacteremic pneumonia in adult patients with community-acquired pneumococcal pneumonia. J Infect. 23 August (Epub ahead of print). DOI: 10.1016/j.jinf.2012.08.011.
71. Kelesidis T. Karageorgopoulos D. Kelesidis I. Falagas M. (2008) Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother. 62: 895–904.
72. Kim C. Hesek D. Zajicek J. Vakulenko S. Mobashery S. (2006) Characterization of the bifunctional aminoglycoside-modifying enzyme ANT(3'')-Ii/AAC(6')-IId from Serratia marcescens. Biochemistry. 45: 8368–8377.
73. Kim C. Villegas-Estrada A. Hesek D. Mobashery S. (2007) Mechanistic characterization of the bifunctional aminoglycoside-modifying enzyme AAC (3)-Ib/AAC(6')-Ib' from Pseudomonas aeruginosa. Biochemistry. 46: 5270–5282.
74. Kim P. Wu Y. Cooper C. Rochester G. Valappil T. Wang Y. et al (2010) Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis. 51: 381–389.
75. Kim Y. Pai H. Lee H. Park S. Choi E. Kim J. et al (2002) Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother. 46: 1481–1491.
76. Kofteridis D. Alexopoulou C. Valachis A. Maraki S. Dimopoulou D. Georgopoulos D. et al (2010) Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis. 51: 1238–1244.
77. Landman D. Georgescu C. Martin D. Quale J. (2008) Polymyxins revisited. Clin Microbiol Rev. 21: 449–465.
78. Lartigue M. Poirel L. Poyart C. Reglier-Poupet H. Nordmann P. (2007) Ertapenem resistance of Escherichia coli. Emerg Infect Dis. 13: 315–317.
79. Lascols C. Hackel M. Marshall S. Hujer A. Bouchillon S. Badal R. et al (2011) Increasing prevalence and dissemination of NDM-1 metallo-beta-lactamase in India: data from the SMART study (2009). J Antimicrob Chemother. 66: 1992–1997.
80. Laupland K. Church D. Vidakovich J. Mucenski M. Pitout J. (2008) Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect. 57: 441–448.
81. Leclercq R. Canton R. Brown D. Giske C. Heisig P. Macgowan A. et al (2011) EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect. 21 October (Epub ahead of print).
82. Lee C. Su L. Tang Y. Liu J. (2006) Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J Antimicrob Chemother. 58: 1074–1077.
83. Lee, N., Lee, C., Huang, W., Tsui, K., Hsueh, P. and Ko, W. (2012) Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis 29 November (Epub ahead of print). DOI: 10.1093/cid/cis916.
84. Lee S. Kuti J. Nicolau D. (2007) Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections. J Infect. 54: 463–468.
85. Livermore D. Hope R. Brick G. Lillie M. Reynolds R. BSAC Working Parties on Resistance Surveillance (2008) Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001–06. J Antimicrob Chemother. 62(Suppl. 2): ii41–ii54.
86. Livermore D. Hope R. Fagan E. Warner M. Woodford N. Potz N. (2006) Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. J Antimicrob Chemother. 57: 1012–1014.
87. Livermore D. Mushtaq S. Warner M. Zhang J. Maharjan S. Doumith M. et al (2011 a) Activities of NXL 104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 55: 390–394.
88. Livermore D. Mushtaq S. Warner M. Zhang J. Maharjan S. Doumith M. et al (2011 b) Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother. 66: 48–53.
89. Lucasti C. Popescu I. Ramesh M. Lipka J. Sable C. (2011) Efficacy and safety of ceftazidime/NXL104 plusmetronidazole vs. meropenem in the treatment of complicated intra-abdominal infections in hospitalised adults. Clin Microbiol Infect. 17(Suppl. 4): S437–S437.
90. MacGowan A. (2008) Breakpoints for extended-spectrum beta-lactamase-producing Enterobacteriacae: pharmacokinetic / pharmacodynamic considerations. Clin Microbiol Infect. 14(Suppl. 1): 166–168.
91. Macone A. Donatelli J. Dumont T. Levy S. Tanaka K. (2003) In vitro activity of PTK 0796 against Gram-positive and Gram-negative organisms. Abstracts Book of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Il, USA. American Society for Microbiology. abstract 2439.
92. Mammeri H. Eb F. Berkani A. Nordmann P. (2008) Molecular characterization of AmpC-producing Escherichia coli clinical isolates recovered in a French hospital. J Antimicrob Chemother. 61: 498–503.
93. Maraki S. Samonis G. Rafailidis P. Vouloumanou E. Mavromanolakis E. Falagas M. (2009) Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother. 53: 4508–4510.
94. Martinez-Martinez L. Pascual A. Jacoby G. (1998) Quinolone resistance from a transferable plasmid. Lancet. 351: 797–799.
95. Matsumura Y. Yamamoto M. Higuchi T. Komori T. Tsuboi F. Hayashi A. et al (2012) Prevalence of plasmid-mediated AmpC β-lactamase-producing Escherichia coli and spread of the ST 131 clone among extended-spectrum β-lactamase-producing E. coli in Japan. Int J Antimicrob Agents. 40: 158–162.
96. Michalopoulos A. Fotakis D. Virtzili S. Vletsas C. Raftopoulou S. Mastora Z. et al (2008) Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med. 102: 407–412.
97. Michalopoulos A. Karatza D. Gregorakos L. (2011) Pharmacokinetic evaluation of colistin sodium. Expert Opin Drug Metab Toxicol. 7: 245–255.
98. Michalopoulos A. Virtzili S. Rafailidis P. Chalevelakis G. Damala M. Falagas M. (2010) Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect. 16: 184–186.
99. Miró E. Aguero J. Larrosa M. Fernandez A. Conejo M. Bou G. et al (2012) Prevalence and molecular epidemiology of acquired AmpC beta-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. Eur J Clin Microbiol Infect Dis. 7 September (Epub ahead of print). DOI 10.1007/s10096–012–1737-0.
100. Mouloudi E. Protonotariou E. Zagorianou A. Iosifidis E. Karapanagiotou A. Giasnetsova T. et al (2010) Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumonia carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol. 31: 1250–1256.
101. Navarro F. Miró E. Mirelis B. (2010) Interpretive reading of enterobacteria antibiograms. Enferm Infecc Microbiol Clin. 28: 638–645.
102. Nicolau D. Carmeli Y. Crank C. Goff D. Graber C. Lima A. et al (2012) Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. Int J Antimicrob Agents. 39: 11–15.
103. Nicolle L. Mulvey M. (2007) Successful treatment of ctx-m ESBL producing Escherichia coli relapsing pyelonephritis with long term pivmecillinam. Scand J Infect Dis. 39: 748–749.
104. Nordmann P. Naas T. Poirel L. (2011) Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 17: 1791–1798.
105. Pai H. Kang C. Byeon J. Lee K. Park W. Kim H. et al (2004) Epidemiology and clinical features of bloodstream infections caused by AmpC-type-beta-lactamase-producing Klebsiella pneumonia. Antimicrob Agents Chemother. 48: 3720–3728.
106. Park Y. Adams-Haduch J. Shutt K. Yarabinec D. 3rd, Johnson L. Hingwe A. et al (2012) Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States. Antimicrob Agents Chemother. 56: 1870–1876.
107. Patel G. Bonomo R. (2011) Status report on carbapenemases: challenges and prospects. Rev Anti Infect Ther. 9: 555–570.
108. Paterson D. (2006) Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect Control. 34: S20–S28. discussion S64–S73.
109. Paterson D. Bonomo R. (2005) Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 18: 657–686.
110. Paterson D. Ko W. von Gottberg A. Casellas J. Mulazimoglu L. Klugman K. et al (2001) Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol. 39: 2206–2212.
111. Paul M. Bishara J. Levcovich A. Chowers M. Goldberg E. Singer P. (2010) Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother. 65: 1019–1027.
112. Peralta G. Lamelo M. Alvarez-Garcia P. Velasco M. Delgado A. Horcajada J. et al (2012) Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study. BMC Infect Dis. 12: 245–246.
113. Perichon B. Courvalin P. Galimand M. (2007) Transferable resistance to aminoglycosides by methylation of G 1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. Antimicrob Agents Chemother. 51: 2464–2469.
114. Pichardo C. Rodriguez-Martinez J. Pachon-Ibanez M. Conejo C. Ibanez-Martinez J. Martinez-Martinez L. et al (2005) Efficacy of cefepime and imipenem in experimental murine pneumonia caused by porin-deficient Klebsiella pneumoniae producing CMY-2 beta-Lactamase. Antimicrob Agents Chemother. 49: 3311–3316.
115. Pitout J. (2010) Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs. 70: 313–333.
116. Pitout J. (2012) Enterobacteriaceae that produce extended-spectrum beta-lactamases and AmpC beta-lactamases in the community: the tip of the iceberg? Curr Pharm Des. 19: 257–263.
117. Pitout J. Le P. Church D. Gregson D. Laupland K. (2008) Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam. Int J Antimicrob Agents. 32: 333–338.
118. Poirel L. Heritier C. Tolun V. Nordmann P. (2004) Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother. 48: 15–22.
119. Pournaras S. Vrioni G. Neou E. Dendrinos J. Dimitroulia E. Poulou A. et al (2011) Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents. 37: 244–247.
120. Prasad P. Sun J. Danner R. Natanson C. (2012) Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis. 54: 1699–1709.
121. Psichogiou M. Tassios P. Avlamis A. Stefanou I. Kosmidis C. Platsouka E. et al (2008) Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey. J Antimicrob Chemother. 61: 59–63.
122. Qureshi Z. Paterson D. Potoski B. Kilayko M. Sandovsky G. Sordillo E. et al (2012) Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 56: 2108–2113.
123. Retamar P. Portillo M. Lopez-Prieto M. Rodriguez-Lopez F. de Cueto M. Garcia M. et al (2012) Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother. 56: 472–478.
124. Reyes N. Aggen J. Kostrub C. (2011) In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models. Antimicrob Agents Chemother. 55: 1728–1733.
125. Rhomberg P. Jones R. (2009) Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999–2008). Diagn Microbiol Infect Dis. 65: 414–426.
126. Robicsek A. Strahilevitz J. Jacoby G. Macielag M. Abbanat D. Park C. et al (2006) Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med. 12: 83–88.
127. Rodriguez-Avial C. Rodriguez-Avial I. Merino P. Picazo J. (2012) Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant patient. Clin Microbiol Infect. 18: 61–66.
128. Rodriguez-Baño J. Alcala J. Cisneros J. Grill F. Oliver A. Horcajada J. et al (2008) Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med. 168: 1897–1902.
129. Rodriguez-Baño J. Miró E. Villar M. Coelho A. Gozalo M. Borrell N. et al (2012 a) Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC beta-lactamases. J Infect. 64: 176–183.
130. Rodriguez-Baño J. Navarro M. Retamar P. Picon E. Pascual A. ESBL-REIPI Group (2012 b) beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 54: 167–174.
131. Rodriguez-Baño J. Pascual A. (2008) Clinical significance of extended-spectrum beta-lactamases. Expert Rev Anti Infect Ther. 6: 671–683.
132. Rodriguez-Baño J. Picon E. Gijon P. Hernandez J. Ruiz M. Pena C. et al (2010) Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis. 50: 40–48.
133. Rodriguez-Baño J. Picon E. Navarro M. Lopez-Cerero L. Pascual A. ESBL-REIPI Group (2012 c) Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli. Clin Microbiol Infect. 18: 894–900.
134. Rodriguez-Martinez J. Fernandez-Echauri P. Fernandez-Cuenca F. Diaz de Alba P. Briales A. Pascual A. (2012) Genetic characterization of an extended-spectrum AmpC cephalosporinase with hydrolysing activity against fourth-generation cephalosporins in a clinical isolate of Enterobacter aerogenes selected in vivo. J Antimicrob Chemother. 67: 64–68.
135. Rogers B. Aminzadeh Z. Hayashi Y. Paterson D. (2011) Country-to-country transfer of patients and the risk of multi-resistant bacterial infection. Clin Infect Dis. 53: 49–56.
136. Rottier W. Ammerlaan H. Bonten M. (2012) Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother. 67: 1311–1320.
137. Ruiz J. (2003) Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother. 51: 1109–1117.
138. Sader H. Rhomberg P. Farrell D. Jones R. (2011) Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother. 55: 2390–2394.
139. Schwaber M. Klarfeld-Lidji S. Navon-Venezia S. Schwartz D. Leavitt A. Carmeli Y. (2008) Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 52: 1028–1033.
140. Senol S. Tasbakan M. Pullukcu H. Sipahi O. Sipahi H. Yamazhan T. et al (2010) Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection. J Chemother. 22: 355–357.
141. Shakil S. Azhar E. Tabrez S. Kamal M. Jabir N. Abuzenadah A. et al (2011) New Delhi metallo-beta-lactamase (NDM-1): an update. J Chemother. 23: 263–265.
142. Simner P. Zhanel G. Pitout J. Tailor F. McCracken M. Mulvey M. et al (2011) Prevalence and characterization of extended-spectrum beta-lactamase- and AmpC beta-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis. 69: 326–334.
143. Skurnik D. Lasocki S. Bremont S. Muller-Serieys C. Kitzis M. Courvalin P. et al (2010) Development of ertapenem resistance in a patient with mediastinitis caused by Klebsiella pneumoniae producing an extended-spectrum beta-lactamase. J Med Microbiol. 59: 115–119.
144. Stone N. Woodford N. Livermore D. Howard J. Pike R. Mushtaq S. et al (2011) Breakthrough bacteraemia due to tigecycline-resistant Escherichia coli with New Delhi metallo-β-lactamase (NDM)-1 successfully treated with colistin in a patient with calciphylaxis. J Antimicrob Chemother. 66: 2677–2678.
145. Sutcliffe J. (2011) Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci. 1241: 122–152.
146. Tangden T. Cars O. Melhus A. Lowdin E. (2010) Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother. 54: 3564–3568.
147. Tasbakan M. Pullukcu H. Sipahi O. Yamazhan T. Ulusoy S. (2012) Nitrofurantoin in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infection. Int J Antimicrob Agents. 40: 554–556.
148. Tasina E. Haidich A. Kokkali S. Arvanitidou M. (2011) Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis. 11: 834–844.
149. Tato M. Coque T. Ruiz-Garbajosa P. Pintado V. Cobo J. Sader H. et al (2007) Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-beta-lactamase in Spain: toward endemicity? Clin Infect Dis. 45: 1171–1178.
150. Titelman E. Iversen A. Kalin M. Giske C. (2012) Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist. 18: 189–192.
151. Titelman E. Karlsson I. Ge Y. Giske C. (2011) In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis. 70: 137–141.
152. Tortola M. Lavilla S. Miró E. Gonzalez J. Larrosa N. Sabate M. et al (2005) First detection of a carbapenem-hydrolyzing metalloenzyme in two enterobacteriaceae isolates in Spain. Antimicrob Agents Chemother. 49: 3492–3494.
153. Tumbarello M. Sanguinetti M. Montuori E. Trecarichi E. Posteraro B. Fiori B. et al (2007) Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother. 51: 1987–1994.
154. Tumbarello M. Viale P. Viscoli C. Trecarichi E. Tumietto F. Marchese A. et al (2012) Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: importance of Combination Therapy. Clin Infect Dis. 55: 943–950.
155. Tuon F. Rocha J. Toledo P. Arend L. Dias C. Leite T. et al (2012) Risk factors for KPC-producing Klebsiella pneumoniae bacteremia. Braz J Infect Dis. 16: 416–419.
156. Turner P. (2009) MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagn Microbiol Infect Dis. 63: 217–222.
157. Tzouvelekis L. Markogiannakis A. Psichogiou M. Tassios P. Daikos G. (2012) Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 25: 682–707.
158. van der Bij A. Pitout J. (2012) The role of international travel in the worldwide spread of multiresistant Enterobacteriaceae. J Antimicrob Chemother. 67: 2090–2100.
159. Vardakas K. Tansarli G. Rafailidis P. Falagas M. (2012) Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 67: 2793–2803.
160. Vazquez J. Gonzalez Patzan L. Lipka J. Sable C. (2011) Efficacy, safety and tolerability of ceftazidime/NXL104 vs. imipenem cilastatin in the treatment of complicated urinary tract infections in hospitalised adults. Clin Microbiol Infect. 17: S438–S438.
161. Vazquez J. González Patzán L. Stricklin D. Duttaroy D. Kreidly Z. Lipka J. et al (2012) Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin. 28: 1921–1931.
162. Vidal L. Gafter-Gvili A. Borok S. Fraser A. Leibovici L. Paul M. (2007) Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 60: 247–257.
163. Vimont S. Aubert D. Mazoit J. Poirel L. Nordmann P. (2007) Broad-spectrum beta-lactams for treating experimental peritonitis in mice due to Escherichia coli producing plasmid-encoded cephalosporinases. J Antimicrob Chemother. 60: 1045–1050.
164. Weisenberg S. Morgan D. Espinal-Witter R. Larone D. (2009) Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem. Diagn Microbiol Infect Dis. 64: 233–235.
165. Wiskirchen D. Crandon J. Furtado G. Williams G. Nicolau D. (2011) In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL 104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. Antimicrob Agents Chemother. 55: 3220–3225.
166. Wu Q. Zhang Y. Han L. Sun J. Ni Y. (2009) Plasmid-mediated 16S rRNA methylases in aminoglycoside-resistant Enterobacteriaceae isolates in Shanghai, China. Antimicrob Agents Chemother. 53: 271–272.
167. Wu U. Chen W. Yang C. Wang J. Hu F. Chang S. et al (2012) Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis. Int J Infect Dis. 16: 47–52.
168. Yahav D. Lador A. Paul M. Leibovici L. (2011) Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 66: 1963–1971.
169. Yahav D. Paul M. Fraser A. Sarid N. Leibovici L. (2007) Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 7: 338–348.
170. Yamane K. Wachino J. Suzuki S. Kimura K. Shibata N. Kato H. et al (2007) New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrob Agents Chemother. 51: 3354–3360.
171. Yilmaz G. Bastug A. But A. Yildiz S. Yetkin M. Kanyilmaz D. et al (2012) Clinical and microbiological efficacy and toxicity of colistin in patients infected with multidrug-resistant gram-negative pathogens. J Infect Chemother. 18 July (Epub ahead of print).
172. Zanetti G. Bally F. Greub G. Garbino J. Kinge T. Lew D. et al (2003) Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother. 47: 3442–3447.
173. Zarkotou O. Pournaras S. Voulgari E. Chrysos G. Prekates A. Voutsinas D. et al (2010) Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study. J Clin Microbiol. 48: 2271–2274.
174. Zhanel G. Baudry P. Tailor F. Cox L. Hoban D. Karlowsky J. (2009) Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. J Antimicrob Chemother. 64: 824–828.
175. Zhang W. Fisher J. Mobashery S. (2009) The bifunctional enzymes of antibiotic resistance. Curr Opin Microbiol. 12: 505–511.